Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.
2.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

3.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators..

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
4.

Switching from prasugrel to clopidogrel: navigating in unknown waters.

Angiolillo DJ, Rollini F.

JACC Cardiovasc Interv. 2013 Feb;6(2):166-8. doi: 10.1016/j.jcin.2012.12.001. No abstract available.

6.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

7.

Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.

Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D.

Am Heart J. 2011 Sep;162(3):518-26.e5. doi: 10.1016/j.ahj.2011.06.005. Epub 2011 Aug 11.

PMID:
21884870
8.

Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.

Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE, Placentino F, Di Roma A, Cavallo E, Palmirotta R, Guadagni F, Fedele F.

Int J Cardiol. 2015 Sep 1;194:60-2. doi: 10.1016/j.ijcard.2015.05.085. Epub 2015 May 15. No abstract available.

PMID:
26011265
9.

Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.

Lhermusier T, Voisin S, Murat G, Mejean S, Garcia C, Bataille V, Lipinski MJ, Carrié D, Sié P.

Int J Cardiol. 2014 Jul 1;174(3):874-6. doi: 10.1016/j.ijcard.2014.04.208. Epub 2014 Apr 26. No abstract available.

PMID:
24820749
10.

Switching from clopidogrel to prasugrel in patients having coronary stent implantation.

Parodi G, De Luca G, Bellandi B, Comito V, Valenti R, Marcucci R, Carrabba N, Migliorini A, Ramazzotti RN, Gensini GF, Abbate R, Antoniucci D.

J Thromb Thrombolysis. 2014 Oct;38(3):395-401.

PMID:
24659131
11.

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.

Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H.

Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25.

PMID:
23615745
12.

High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?

Goto S, Tomiya A.

Thromb Haemost. 2013 Feb;109(2):177-8. doi: 10.1160/TH12-12-0910. Epub 2013 Jan 10. No abstract available.

PMID:
23306954
13.

Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.

Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L.

Platelets. 2014;25(7):506-12. doi: 10.3109/09537104.2013.845874. Epub 2013 Nov 18.

PMID:
24245960
14.

Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A.

J Am Coll Cardiol. 2013 May 21;61(20):2060-6. doi: 10.1016/j.jacc.2013.02.036. Epub 2013 Mar 21.

15.

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Apr;7(4):426-34. doi: 10.1016/j.jcin.2013.11.019. Epub 2014 Mar 13.

16.

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R.

Am J Cardiol. 2013 Mar 15;111(6):841-5. doi: 10.1016/j.amjcard.2012.11.058. Epub 2012 Dec 27.

PMID:
23273719
17.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
18.

Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.

Capranzano P, Tamburino C, Capodanno D, Miccichè E, D'Urso L, Calvi V, Angiolillo DJ, Tamburino C.

Thromb Haemost. 2011 Dec;106(6):1149-57. doi: 10.1160/TH11-05-0346. Epub 2011 Oct 20.

PMID:
22011914
19.

High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.

Bernlochner I, Mayer K, Morath T, Braun S, Schulz S, Schömig A, Koch W, Kastrati A, Sibbing D.

Platelets. 2013;24(6):500-2. doi: 10.3109/09537104.2012.715218. Epub 2012 Aug 23. No abstract available.

PMID:
22916844
20.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

Supplemental Content

Support Center